Article | November 14, 2022

How To Overcome The Problem Of The Early ePRO Oversell

Source: Medrio

By Fred Martin, Chief Operating Officer

Patient Reported Outcome ePRO

Does this sound familiar? You implemented ePRO during the pandemic, or maybe even before it, and were excited by the promise of better participant engagement, increased participant compliance, and greater efficiency. Yet, the reality did not live up to the hype.

While your vendor promised you a straightforward implementation, you found the actual process to be overly complicated, time-consuming, costly, and frustrating. You did not realize the expected benefits of ePRO, and maybe you have even reverted back to paper processes or are only using ePRO for your most complex studies.

Yet, in today’s environment, you also know that you need to reconsider your approach to PROs, given increasing regulations and trial scrutiny, the clinical need for patient-reported outcomes, and the ability to drive costs down and move off paper.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader